Table Filtering
Other Information
Release Statistics Download
GlyCosmos Glycolipids

Glycolipid entries from the LIPID MAPS Structure Database (LMSD).

Source Last Updated
LIPID MAPS Proteome Database (LMSD) June 16, 2024
Displaying entries 276 - 300 of 3913 in total
Main Class Sub Class LM ID Name LipidBank ID KEGG ID PubChem CID ▲ ChEBI ID Exact Mass Formula
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AI06
  • Fucalpha1-2Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:0)
  • type IV H(d18:1/26:0)
44260233 1675.017178 C82H150N2O32
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AI07
  • Fucalpha1-2Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
  • type IV H(d18:1/24:1(15Z))
44260234 1644.970228 C80H144N2O32
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AI08
  • Fucalpha1-2Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
  • type IV H(d18:1/26:1(17Z))
44260235 1673.001528 C82H148N2O32
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AJ01
  • GalNAcalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/16:0)
  • type IV A antigen(d18:1/16:0)
44260236 1737.940052 C80H143N3O37
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AJ02
  • GalNAcalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/18:0)
  • type IV A antigen(d18:1/18:0)
44260237 1765.971352 C82H147N3O37
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AJ03
  • GalNAcalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/20:0)
  • type IV A antigen(d18:1/20:0)
44260238 1794.002652 C84H151N3O37
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AJ04
  • GalNAcalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/22:0)
  • type IV A antigen(d18:1/22:0)
44260239 1822.033952 C86H155N3O37
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AJ05
  • GalNAcalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:0)
  • type IV A antigen(d18:1/24:0)
44260240 1850.065252 C88H159N3O37
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AJ06
  • GalNAcalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:0)
  • type IV A antigen(d18:1/26:0)
44260241 1878.096552 C90H163N3O37
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AJ07
  • GalNAcalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
  • type IV A antigen(d18:1/24:1(15Z))
44260242 1848.049602 C88H157N3O37
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AJ08
  • GalNAcalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
  • type IV A antigen(d18:1/26:1(17Z))
44260243 1876.080902 C90H161N3O37
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AK01
  • Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/16:0)
  • type IV B antigen(d18:1/16:0)
44260244 1696.913503 C78H140N2O37
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AK02
  • Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/18:0)
  • type IV B antigen(d18:1/18:0)
44260245 1724.944803 C80H144N2O37
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AK03
  • Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/20:0)
  • type IV B antigen(d18:1/20:0)
44260246 1752.976103 C82H148N2O37
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AK04
  • Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/22:0)
  • type IV B antigen(d18:1/22:0)
44260247 1781.007403 C84H152N2O37
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AK05
  • Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:0)
  • type IV B antigen(d18:1/24:0)
44260248 1809.038703 C86H156N2O37
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AK06
  • Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:0)
  • type IV B antigen(d18:1/26:0)
44260249 1837.070003 C88H160N2O37
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AK07
  • Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
  • type IV B antigen(d18:1/24:1(15Z))
44260250 1807.023053 C86H154N2O37
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AK08
  • Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
  • type IV B antigen(d18:1/26:1(17Z))
44260251 1835.054353 C88H158N2O37
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AL01
  • Galalpha1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/16:0)
44260252 1185.723394 C58H107NO23
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AL02
  • Galalpha1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44260253 1213.754694 C60H111NO23
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AL03
  • Galalpha1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/20:0)
44260254 1241.785994 C62H115NO23
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AL04
  • Galalpha1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/22:0)
44260255 1269.817294 C64H119NO23
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AL05
  • Galalpha1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:0)
44260256 1297.848594 C66H123NO23
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AL06
  • Galalpha1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:0)
44260257 1325.879894 C68H127NO23

About Release Notes Help Feedback

Click here to visit the beta site.


International Collaboration

GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.

Acknowledgements

Supported by JST NBDC Grant Number JPMJND2204

Partly supported by NIH Common Fund Grant #1U01GM125267-01


Logo License Policies Site Map

Contact: support@glycosmos.org

This work is licensed under Creative Commons Attribution 4.0 International


GlyCosmos Portal v4.1.0

Last updated: December 9, 2024